Ayumu Taguchi

List of Publications by Year
in descending order

		126907	161849
55 papers	**3,989** citations	**33** h-index	**54** g-index
56 all docs	**56** docs citations	**56** times ranked	**7477** citing authors

#	Article	IF	Citations
1	Identification of Hypoxia-Inducible Factor-1α as a Novel Target for *miR-17-92* MicroRNA Cluster. Cancer Research, 2008, 68, 5540-5545.	0.9	290
2	*Interleukin-8* Promoter Polymorphism Increases the Risk of Atrophic Gastritis and Gastric Cancer in Japan. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2487-2493.	2.5	235
3	Lineage-Specific Dependency of Lung Adenocarcinomas on the Lung Development Regulator TTF-1. Cancer Research, 2007, 67, 6007-6011.	0.9	200
4	Molecular Portraits of Epithelial, Mesenchymal, and Hybrid States in Lung Adenocarcinoma and Their Relevance to Survival. Cancer Research, 2015, 75, 1789-1800.	0.9	179
5	Endoscopic resection of Peutz-Jeghers polyps throughout the small intestine at double-balloon enteroscopy without laparotomy. Gastrointestinal Endoscopy, 2005, 61, 140-147.	1.0	178
6	Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1555-64.	7.1	174
7	Lung Cancer Signatures in Plasma Based on Proteome Profiling of Mouse Tumor Models. Cancer Cell, 2011, 20, 289-299.	16.8	158
8	Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Molecular Cell, 2016, 61, 520-534.	9.7	142
9	Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer. International Journal of Molecular Sciences, 2017, 18, 573.	4.1	130
10	Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature, 2019, 568, 410-414.	27.8	129
11	*miR-375* Is Activated by ASH1 and Inhibits YAP1 in a Lineage-Dependent Manner in Lung Cancer. Cancer Research, 2011, 71, 6165-6173.	0.9	124
12	*MDM2* Promoter Polymorphism Is Associated With Both an Increased Susceptibility to Gastric Carcinoma and Poor Prognosis. Journal of Clinical Oncology, 2006, 24, 4434-4440.	1.6	122
13	Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Nature Communications, 2019, 10, 254.	12.8	120
14	The grand challenge to decipher the cancer proteome. Nature Reviews Cancer, 2010, 10, 652-660.	28.4	117
15	Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. Journal of the National Cancer Institute, 2017, 109, djw266.	6.3	116
16	Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. JAMA Oncology, 2018, 4, e182078.	7.1	109
17	Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non–Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B. Journal of Clinical Oncology, 2015, 33, 3880-3886.	1.6	88
18	MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway. Cancer Research, 2017, 77, 4414-4425.	0.9	85

#	Article	IF	Citations
19	Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11â€21 in human lung cancer. Genes Chromosomes and Cancer, 2008, 47, 810-818.	2.8	81
20	Small-bowel obstruction: diagnostic comparison between double-balloon endoscopy and fluoroscopic enteroclysis, and the outcome of enteroscopic treatment. Gastrointestinal Endoscopy, 2009, 69, 84-93.	1.0	79
21	A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. Journal of the National Cancer Institute, 2019, 111, 372-379.	6.3	79
22	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology, 2020, 159, 2146-2162.e33.	1.3	75
23	Proâ€"Surfactant Protein B As a Biomarker for Lung Cancer Prediction. Journal of Clinical Oncology, 2013, 31, 4536-4543.	1.6	73
24	Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. Journal of the National Cancer Institute, 2015, 107, .	6.3	72
25	CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Nonâ€"Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 1378-1388.	1.1	71
26	Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry. Metabolites, 2015, 5, 192-210.	2.9	69
27	Role of CPS1 in Cell Growth, Metabolism, and Prognosis in LKB1-Inactivated Lung Adenocarcinoma. Journal of the National Cancer Institute, 2017, 109, djw231.	6.3	69
28	Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma. Oncotarget, 2017, 8, 95466-95480.	1.8	60
29	Unleashing the Power of Proteomics to Develop Blood-Based Cancer Markers. Clinical Chemistry, 2013, 59, 119-126.	3.2	52
30	Application of Proteomics to Cancer Early Detection. Cancer Journal (Sudbury, Mass), 2011, 17, 423-428.	2.0	47
31	Novel urinary protein biomarker panel for early diagnosis of gastric cancer. British Journal of Cancer, 2020, 123, 1656-1664.	6.4	42
32	Integrated mass spectrometryâ€"based analysis of plasma glycoproteins and their glycan modifications. Nature Protocols, 2011, 6, 253-269.	12.0	41
33	A Search for Novel Cancer/Testis Antigens in Lung Cancer Identifies VCX/Y Genes, Expanding the Repertoire of Potential Immunotherapeutic Targets. Cancer Research, 2014, 74, 4694-4705.	0.9	40
34	Enrichment strategies in glycomicsâ€based lung cancer biomarker development. Proteomics - Clinical Applications, 2013, 7, 664-676.	1.6	34
35	Interleukin-8 gene polymorphism associated with susceptibility to non-cardia gastric carcinoma with microsatellite instability. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 1129-1135.	2.8	32
36	The association between tumour necrosis factor-Î± gene polymorphism and the susceptibility to rugal hyperplastic gastritis and gastric carcinoma. European Journal of Gastroenterology and Hepatology, 2004, 16, 693-700.	1.6	30

#	Article	IF	Citations
37	Switching Roles of TGF-Î² in Cancer Development: Implications for Therapeutic Target and Biomarker Studies. Journal of Clinical Medicine, 2016, 5, 109.	2.4	30
38	MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas. Cancer Prevention Research, 2015, 8, 1112-1119.	1.5	25
39	Circulating Pro-Surfactant Protein B as a Risk Biomarker for Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1756-1761.	2.5	24
40	Proteomic signatures associated with p53 mutational status in lung adenocarcinoma. Proteomics, 2014, 14, 2750-2759.	2.2	20
41	SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1â€"Negative Lung Adenocarcinomas. Journal of the National Cancer Institute, 2022, 114, 290-301.	6.3	18
42	Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma. Cancers, 2022, 14, 2543.	3.7	16
43	Serum Glycans as Risk Markers for Nonâ€"Small Cell Lung Cancer. Cancer Prevention Research, 2016, 9, 317-323.	1.5	15
44	Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma. Cancer Science, 2021, 112, 1225-1234.	3.9	15
45	HIV Infection and Circulating Levels of Prosurfactant Protein B and Surfactant Protein D. Journal of Infectious Diseases, 2018, 217, 413-417.	4.0	8
46	Conditional <i>Ror1</i> knockout reveals crucial involvement in lung adenocarcinoma development and identifies novel HIFâ€1Î± regulator. Cancer Science, 2021, 112, 1614-1623.	3.9	8
47	Severity of atrophic gastritis related to antiparietal cell antibody and gastric carcinogenesis, including p53 mutations. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 545-551.	2.8	7
48	A Promising CPS1 Inhibitor Keeping Ammonia from Fueling Cancer. Cell Chemical Biology, 2020, 27, 253-254.	5.2	6
49	Identification of Blood-Based Biomarkers for the Prediction of the Response to Neoadjuvant Chemoradiation in Rectal Cancer. Cancers, 2021, 13, 3642.	3.7	6
50	Rugal hyperplastic gastritis increases the risk of gastric carcinoma, especially diffuse and p53-independent subtypes. European Journal of Gastroenterology and Hepatology, 2007, 19, 561-566.	1.6	5
51	Mouse to Human Blood-Based Cancer Biomarker Discovery Strategies. Cold Spring Harbor Protocols, 2014, 2014, pdb.top078808.	0.3	5
52	Deciphering the complexity of the cancer proteome for diagnostic applications. Expert Review of Molecular Diagnostics, 2016, 16, 399-405.	3.1	5
53	A Statistical Method for Detecting Differentially Expressed SNVs Based on Next-Generation RNA-Seq Data. Biometrics, 2017, 73, 42-51.	1.4	2
54	Cancer proteomics. , 0, , 52-57.		0

#	Article	IF	Citations
55	Harnessing Immune Response to Malignant Lung Nodules. Promise and Challenges. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1184-1186.	5.6	0